China's Hansoh Signs up to $1.45 Billion Deal for Colorectal Cancer Drug With Roche
Published by Global Banking & Finance Review®
Posted on October 16, 2025
1 min readLast updated: January 21, 2026
Add as preferred source on GooglePublished by Global Banking & Finance Review®
Posted on October 16, 2025
1 min readLast updated: January 21, 2026
Add as preferred source on GoogleHansoh Pharma has entered a $1.45 billion licensing agreement with Roche for a colorectal cancer drug, expanding its oncology offerings.
(Reuters) -Chinese biotech Hansoh Pharma said on Friday its units have signed a license agreement worth up to $1.45 billion with Roche's subsidiary for an investigational treatment of colorectal cancer and other solid tumors.
(Reporting by Sneha Kumar in Bengaluru; Editing by Shailesh Kuber)
Colorectal cancer is a type of cancer that starts in the colon or rectum. It is one of the most common types of cancer and can be influenced by factors like diet and genetics.
A subsidiary is a company that is completely or partially owned and controlled by another company, known as the parent company.
Explore more articles in the Headlines category